Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
How the Congenital Heart Disease (CHD) Market Has Progressed: A Look Back Over the Past Few Years?
The market size for congenital heart disease (chd) has seen substantial expansion in recent times. The market is predicted to surge from $4.42 billion in 2024 to $4.85 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.7%.
The growth during the historical period is attributable to a rise in risk factor prevalence like obesity and smoking, advancements in diagnostic technologies, an enlarging population of senior citizens, amplified awareness drives, improved reimbursement policies, and an escalation in investment towards research and development.
The market size of congenital heart disease (chd) is predicted to experience substantial growth in the upcoming years, anticipated to reach $6.82 billion in 2029, with a compound annual growth rate (CAGR) of 8.9%. This growth during the forecast period can be linked to increased availability of healthcare services in emerging regions, ongoing advancements in cardiac imaging technology, wide-ranging awareness campaigns for early detection and treatment, escalated worldwide healthcare spending, and the emergence of personalized medicine.
Key trends during the forecast period encompass the embracement of less invasive surgical methods, extended deployment of telemedicine for remote patient tracking and consultations, increased demand for personalized treatment methods, the invention of advanced implantable devices boasting enhanced functionality and durability, and the incorporation of artificial intelligence and machine learning in diagnostic and treatment procedures.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What’s Driving the Upward Growth Trajectory of the Congenital Heart Disease (CHD) Market?
The surge in instances of maternal diabetes is predicted to fuel the expansion of the congenital heart disease (CHD) market in the future. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is characterized by the onset of diabetes in pregnant women who had no prior history of the condition.
Lifestyle changes such as lack of exercise and poor diet, as well as an overall increase in obesity amongst reproductive-age women, are the chief causes of maternal diabetes. This condition is capable of leading to congenital heart disease (CHD) in newborns, since high blood sugar can adversely affect the heart development of the fetus.
The excessive glucose in the expecting mother’s bloodstream can hinder the proper growth of the baby’s heart, thereby heightening CHD risks. For example, the National Health Service, a government department from the UK, stated in October 2023 that negative pregnancy outcomes among women diagnosed with type 2 diabetes in 2021 accounted for 4.9%, yet it increased to 6.6% in 2022.
Hence, the rise in maternal diabetes instances is spurring on the growth of the congenital heart disease (CHD) market.
Which Segments in the Congenital Heart Disease (CHD) Industry Are Seeing the Fastest Growth?
The congenital heart disease (chd)market covered in this report is segmented –
1) By Type: Heart Valve Defects; Heart Wall Defects; Blood Vessel Defects; Other Types
2) By Diagnosis: Electrocardiogram; Chest X-ray; Echocardiogram; Transesophageal Echocardiogram; Pulse Oximetry; Exercise Stress Test; Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI); Cardiac Catheterization; Other Diagnosis
3) By Treatment: Interventional Cardiology; Cardiac Surgery; Telemedicine; Medication Management; Lifestyle Modifications
4) By Age Group: Infants; Children; Adolescents; Adults
5) By Application: Hospitals And Clinics; Diagnostic Centers; Ambulatory Surgical Centers; Research And Academic Institutions
Subsegments:
1) By Heart Valve Defects: Aortic Valve Stenosis; Pulmonary Valve Stenosis; Mitral Valve Prolapse; Tricuspid Valve Defects; Valve Regurgitation
2) By Heart Wall Defects: Atrial Septal Defect (ASD); Ventricular Septal Defect (VSD); Atrioventricular Septal Defect (AVSD); Hypoplastic Left Heart Syndrome (HLHS); Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta; Patent Ductus Arteriosus (PDA); Pulmonary Artery Stenosis; Transposition Of The Great Arteries (TGA); Truncus Arteriosus
4) By Other Types: Single Ventricle Defects; Ebstein’s Anomaly; Total Anomalous Pulmonary Venous Return (TAPVR); Coronary Artery Anomalies; Pulmonary Venous Obstruction
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
How Will Shifting Market Trends Influence Congenital Heart Disease (CHD) System Adoption?
Leading firms in the congenital heart disease market are trailblazing the development of non-invasive heart valves to enhance the health outcomes and lifestyle quality of patients. Transcatheter, or non-surgical heart valves, are innovative medical aids designed to handle heart valve diseases without necessitating traditional open-heart surgical procedures.
To illustrate, in February 2023, Medtronic, a medical technology corporation based in the U.S., re-launched its cutting-edge Harmony Transcatheter Pulmonary Valve (TPV) System. This minimally invasive substitute for open-heart surgery has been devised to assist patients suffering from congenital heart disease, particularly those diagnosed with either native or surgically corrected right ventricular outflow tract (RVOT) irregularities.
The Harmony TPV System is distinguished as the first valve to get FDA approval for right-side usage, offering a non-surgical option for patients dealing with severe pulmonary valve regurgitation. After voluntarily recalling it, Medtronic received U.S.
FDA approval to reintroduce the Harmony TPV System in 2021. This bold move confirms Medtronic’s dedication to enhancing solutions for individuals with congenital heart disease.
Which Global Regions Are Powering Demand in the Congenital Heart Disease (CHD) Market?
North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
How Key Players Are Driving Growth in the Congenital Heart Disease (CHD) Market?
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=15545
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
